Abstract
The present study was designed to investigate the role of D4 dopamine receptors in regulating the Akt/nuclear factor-κB (NF-κB) and extracellular signal-regulated kinase (ERK) signaling pathways. The D4 dopamine receptor agonist PD168077 induced time- and dose-dependent activation of Akt and ERK in D4MN9D cells that stably express D4 dopamine receptors. Maximal Akt and ERK stimulation was achieved at 1 μM PD168077. The agonist-mediated stimulations of Akt and ERK were abolished when cells were preincubated with 50 ng/ml PTX or with 1 μM L745,870, a D4 dopamine receptor antagonist, indicating that activation of the Akt or ERK pathways is mediated by D4 dopamine receptors and require a pertussis toxin-sensitive G protein. We also detected a time- and dose-dependent activation of NF-κB. Activation of NF-κB by 1 μM PD168077 was attenuated in D4MN9D cells that were transfected with a kinase-deficient Akt but not in cells transfected with a dominant negative Ras (N17Ras), suggesting that NF-κB activation requires Akt but is independent of Ras. In contrast, the transfection of N17Ras into D4MN9D cells blunted D4 dopamine receptor-mediated ERK activation, indicating a Ras-dependent mechanism. Moreover, PP2 (20 nM), an inhibitor of Src, blocked D4receptor-mediated SHC phosphorylation and ERK activation. In contrast, transfection of a kinase-dead Akt did not alter D4receptor-stimulated ERK. However, PP2 and the mitogen activated protein kinase kinase inhibitor PD98059 did not change D4receptor-mediated Akt/NF-κB activation. All these indicate that distinct mechanisms mediate ERK and Akt/NF-κB activation by D4 dopamine receptor stimulation. We also demonstrated that D4 receptor-stimulated cell proliferation is mediated by the Src/SHC/Ras/ERK pathway.
Footnotes
-
This work was supported by United State Public Health Service Grants NS29514 and DA11029.
- Abbreviations:
- GPCR
- G protein-coupled receptor
- MAPK
- mitogen activated protein kinase
- ERK
- extracellular signal-regulated kinase
- PTX
- pertussis toxin
- MAP
- mitogen activated protein
- SHC
- Src homology 2-containing protein
- MBP
- myelin basic protein
- DMEM
- Dulbecco's modified Eagle's medium
- FBS
- fetal bovine serum
- PMSF
- phenylmethylsulfonyl fluoride
- DTT
- dithiothreitol
- PKI
- protein kinase A inhibitor
- EMSA
- electrophoretic mobility shift assay
- Received February 21, 2001.
- Accepted July 12, 2001.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|